Last reviewed · How we verify
Hydroxyethyl Starch
At a glance
| Generic name | Hydroxyethyl Starch |
|---|---|
| Also known as | Hemoes, Colloid, HES, HES 130/0.4, Voluven |
| Sponsor | Hospital de Cruces |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing Reduction With ESD- Versus APC-TORe (NA)
- Re-bleeding in Giant Meningioma and Intraoperative Hydroxyethyl Starch (HES) Fluid Therapy
- Hydroxyethyl Starch Versus Crystalloid and Postoperative Major Adverse Kidney Complications (PHASE4)
- Crystalloid vs Colloid for Hemodynamics During Anesthesia Induction in TAVR Patients (NA)
- Optimized Strict Fluid Management Helps Improve Endpoints After Liver Dissection (NA)
- Cardiac Output in Preeclamptic (NA)
- Optimizing Fluid Resuscitation in Adults With Major Burns: A Randomized Trial of Burn Navigator™ Versus Parkland Formula (PHASE4)
- Priming of Cardiopulmonary Bypass With Hydroxyethyl Starch 130/0.4 or Sodium Chloride 0.9% : Pilot Study in Adult Elective Conventional Cardiac Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydroxyethyl Starch CI brief — competitive landscape report
- Hydroxyethyl Starch updates RSS · CI watch RSS
- Hospital de Cruces portfolio CI